Cargando…
A model based on the quantification of complement C4c, CYFRA 21–1 and CRP exhibits high specificity for the early diagnosis of lung cancer
Lung cancer screening detects early-stage cancers, but also a large number of benign nodules. Molecular markers can help in the lung cancer screening process by refining inclusion criteria or guiding the management of indeterminate pulmonary nodules. In this study, we developed a diagnostic model ba...
Autores principales: | AJONA, DANIEL, REMIREZ, ANA, SAINZ, CRISTINA, BERTOLO, CRISTINA, GONZALEZ, ALVARO, VARO, NEREA, LOZANO, MARÍA D, ZULUETA, JAVIER J, MESA-GUZMAN, MIGUEL, MARTIN, ANA C, PEREZ-PALACIOS, ROSA, PEREZ-GRACIA, JOSE LUIS, MASSION, PIERRE P, MONTUENGA, LUIS M, PIO, RUBEN |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931205/ https://www.ncbi.nlm.nih.gov/pubmed/33618009 http://dx.doi.org/10.1016/j.trsl.2021.02.009 |
Ejemplares similares
-
Complement C4d-specific antibodies for the diagnosis of lung cancer
por: Ajona, Daniel, et al.
Publicado: (2017) -
Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer
por: Ajona, Daniel, et al.
Publicado: (2015) -
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
por: Redin, Esther, et al.
Publicado: (2021) -
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
por: Hsu, Yi-Fan, et al.
Publicado: (2010) -
Molecular biomarkers in early stage lung cancer
por: Rodríguez, María, et al.
Publicado: (2021)